SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Grönberg Henrik) ;srt2:(2010-2014)"

Sökning: WFRF:(Grönberg Henrik) > (2010-2014)

  • Resultat 21-30 av 30
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Reynolds, Chandra A, et al. (författare)
  • Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk.
  • 2010
  • Ingår i: Human molecular genetics. - : Oxford University Press (OUP). - 1460-2083 .- 0964-6906. ; 19:10, s. 2068-2078
  • Tidskriftsartikel (refereegranskat)abstract
    • We conducted dense linkage disequilibrium mapping of a series of 25 genes putatively involved in lipid metabolism in 1567 dementia cases (including 1270 with Alzheimer disease) and 2203 Swedish controls. Across a total of 448 tested genetic markers, the strongest evidence of association was as anticipated for APOE (rs429358 at p approximately 10(-72)) followed by a previously reported association of ABCA1 (rs2230805 at p approximately 10(-8)). In the present study we report two additional markers near the SREBF1 locus on chromosome 17p that were also significant after multiple testing correction (best p=3.1 x 10(-6) for marker rs3183702). There was no convincing evidence of association for remaining genes, including candidates highlighted from recent genome-wide association studies of plasma lipids (CELSR2/PSRC1/SORT1, MLXIPL, PCSK9, GALNT2, and GCKR). The associated markers near SREBF1 reside in a large linkage disequilibrium block, extending more than 400kb across 7 candidate genes. Secondary analyses of gene expression levels of candidates spanning the LD region together with an investigation of gene network context highlighted two possible susceptibility genes including ATPAF2 and TOM1L2. Several markers in strong LD (r(2)>0.7) with rs3183702 were found to be significantly associated with AD risk in recent genome-wide association studies with similar effect sizes, providing independent support of the current findings.
  •  
22.
  •  
23.
  • Szulkin, Robert, et al. (författare)
  • Prostate cancer risk variants are not associated with disease progression
  • 2012
  • Ingår i: The Prostate. - : Wiley. - 0270-4137 .- 1097-0045. ; 72:1, s. 30-39
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Currently used prognostic markers are limited in their ability to accurately predict disease progression among patients with localized prostate cancer. We examined 23 reported prostate cancer susceptibility variants for association with disease progression. METHODS: Disease progression was explored among 4,673 Swedish patients treated for clinically localized prostate cancer between 1997 and 2002. Prostate cancer progression was defined according to primary treatment as a composed event reflecting termination of deferred treatment, biochemical recurrence, local progression, or presence of distant metastasis. Association between single variants, and all variants combined, were performed in Cox regression analysis assuming both log-additive and co-dominant genetic models. RESULTS: Three of the 23 genetic variants explored were nominally associated with prostate cancer progression; rs9364554 (P = 0.041) on chromosome 6q25 and rs10896449 (P = 0.029) on chromosome 11q13 among patients treated with curative intent; and rs4054823 (P = 0.008) on chromosome 17p12 among patients on surveillance. However, none of these associations remained statistically significant after correction for multiple testing. The combined effect of all susceptibility variants was not associated with prostate cancer progression neither among patients receiving treatment with curative intent (P = 0.14) nor among patients on surveillance (P = 0.92). CONCLUSIONS: We observed no evidence for an association between any of 23 established prostate cancer genetic risk variants and disease progression. Accumulating evidence suggests separate genetic components for initiation and progression of prostate cancer. Future studies systematically searching for genetic risk variants associated with prostate cancer progression and prognosis are warranted. Prostate © 2011 Wiley-Liss, Inc.
  •  
24.
  • Teerlink, Craig C., et al. (författare)
  • Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease
  • 2014
  • Ingår i: Human Genetics. - : Springer. - 0340-6717 .- 1432-1203. ; 133:3, s. 347-356
  • Tidskriftsartikel (refereegranskat)abstract
    • Previous GWAS studies have reported significant associations between various common SNPs and prostate cancer risk using cases unselected for family history. How these variants influence risk in familial prostate cancer is not well studied. Here, we analyzed 25 previously reported SNPs across 14 loci from prior prostate cancer GWAS. The International Consortium for Prostate Cancer Genetics (ICPCG) previously validated some of these using a family-based association method (FBAT). However, this approach suffered reduced power due to the conditional statistics implemented in FBAT. Here, we use a case-control design with an empirical analysis strategy to analyze the ICPCG resource for association between these 25 SNPs and familial prostate cancer risk. Fourteen sites contributed 12,506 samples (9,560 prostate cancer cases, 3,368 with aggressive disease, and 2,946 controls from 2,283 pedigrees). We performed association analysis with Genie software which accounts for relationships. We analyzed all familial prostate cancer cases and the subset of aggressive cases. For the familial prostate cancer phenotype, 20 of the 25 SNPs were at least nominally associated with prostate cancer and 16 remained significant after multiple testing correction (p a parts per thousand currency sign 1E (-3)) occurring on chromosomal bands 6q25, 7p15, 8q24, 10q11, 11q13, 17q12, 17q24, and Xp11. For aggressive disease, 16 of the SNPs had at least nominal evidence and 8 were statistically significant including 2p15. The results indicate that the majority of common, low-risk alleles identified in GWAS studies for all prostate cancer also contribute risk for familial prostate cancer, and that some may contribute risk to aggressive disease.
  •  
25.
  •  
26.
  • Vikström, Anna C., et al. (författare)
  • Alcohol influence on acrylamide to glycidamide metabolism assessed with hemoglobin-adducts and questionnaire data
  • 2010
  • Ingår i: Food and Chemical Toxicology. - : Elsevier BV. - 0278-6915 .- 1873-6351. ; 58:3, s. 820-824
  • Tidskriftsartikel (refereegranskat)abstract
    • Our purpose was to investigate whether alcohol (ethanol) consumption could have an influence on the metabolism of acrylamide to glycidamide in humans exposed to acrylamide through food. We studied a subsample from a population-based case–control study of prostate cancer in Sweden (CAPS). Questionnaire data for alcohol intake estimates was compared to the ratio of hemoglobin-adduct levels for acrylamide and glycidamide, used as a measure of individual differences in metabolism. Data from 161 non-smoking men were processed with regard to the influence of alcohol on the metabolism of acrylamide to glycidamide. A negative, linear trend of glycidamide-adduct to acrylamide-adduct-level ratios with increasing alcohol intake was observed and the strongest association (p-value for trend = 0.02) was obtained in the group of men with the lowest adduct levels (⩽47 pmol/g globin) when alcohol intake was stratified by acrylamide-adduct levels. The observed trend is likely due to a competitive effect between ethanol and acrylamide as both are substrates for cytochrome P450 2E1. Our results, strongly indicating that ethanol influence metabolism of acrylamide to glycidamide, partly explain earlier observations of only low to moderate associations between questionnaire data on dietary acrylamide intake and hemoglobin-adduct levels.
  •  
27.
  • Wiinikka, Henrik, et al. (författare)
  • Emissions of heavy metals during fixed-bed combustion of six biomass fuels
  • 2013
  • Ingår i: Energy & Fuels. - : American Chemical Society (ACS). - 0887-0624 .- 1520-5029. ; 27:2, s. 1073-1080
  • Tidskriftsartikel (refereegranskat)abstract
    • Few studies examine heavy metal emissions during the small-scale combustion of various solid biofuels. This issue may become more important, as one can expect new regulations governing such emissions from biomass combustion similar to those governing waste incineration. This paper investigates the emissions of particulate-associated heavy metals (i.e., Sb, As, Cd, Co, Cr, Cu, Pb, Mn, Ni, Tl, V, Hg, and Zn) during the fixed-bed combustion of six solid biofuels (i.e., stemwood from birch and pine/spruce, bark from birch and pine, salix, and oat grains) and of peat and bituminous coal for comparison. The results indicate that the flue gas concentration (normalized to 11% O2) of the sum of all measured metals (Zn excluded) during the biomass combustion tests ranged from 57 μg Nm-3 for birch stemwood to 198 μg Nm-3 for birch bark. The concentration of Zn in the flue gas was generally considerably higher than those of the other metals, ranging from 646 μg Nm-3 for spruce/pine stemwood to 7948 μg Nm-3 for birch bark. Compared with coal and peat, the biomass fuels produced higher Zn emissions, but lower or similar emissions of the sum of the other metals. The volatile behavior and concentration of the metal in the flue gases as a function of the heavy metal in the fuel are also presented for selected heavy metals.
  •  
28.
  •  
29.
  • Wiklund, Fredrik E, et al. (författare)
  • Macrophage inhibitory cytokine-1 (MIC-1/GDF15) : a new marker of all-cause mortality
  • 2010
  • Ingår i: Aging Cell. - : Wiley. - 1474-9718 .- 1474-9726. ; 9:6, s. 1057-1064
  • Tidskriftsartikel (refereegranskat)abstract
    • Macrophage inhibitory cytokine-1 (MIC-1/GDF15) is a member of the TGF-b superfamily, previously studied in cancer and inflammation. In addition to regulating body weight, MIC-1/GDF15 may be used to predict mortality and/or disease course in cancer, cardiovascular disease (CVD), chronic renal and heart failure, as well as pulmonary embolism. These data suggested that MIC-1/GDF15 may be a marker of all-cause mortality. To determine whether serum MIC-1/GDF15 estimation is a predictor of all-cause mortality, we examined a cohort of 876 male subjects aged 35-80 years, selected from the Swedish Population Registry, and followed them for overall mortality. Serum MIC-1/GDF15 levels were determined for all subjects from samples taken at study entry. A second (independent) cohort of 324 same-sex twins (69% female) from the Swedish Twin Registry was similarly examined. All the twins had telomere length measured and 183 had serum levels of interleukin 6 (IL-6) and C-reactive protein (CRP) available. Patients were followed for up to 14 years and had cause-specific and all-cause mortality determined. Serum MIC-1/GDF15 levels predicted mortality in the all-male cohort with an adjusted odds ratio (OR) of death of 3.38 (95%CI 1.38-8.26). This finding was validated in the twin cohort. Serum MIC-1/GDF15 remained an independent predictor of mortality when further adjusted for telomere length, IL-6 and CRP. Additionally, serum MIC-1/GDF15 levels were directly correlated with survival time independently of genetic background. Serum MIC-1/GDF15 is a novel predictor of all-cause mortality.
  •  
30.
  • Xu, Jianfeng, et al. (författare)
  • Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.
  • 2010
  • Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 1091-6490 .- 0027-8424. ; 107:5, s. 2136-40
  • Tidskriftsartikel (refereegranskat)abstract
    • Autopsy studies suggest that most aging men will develop lesions that, if detected clinically, would be diagnosed as prostate cancer (PCa). Most of these cancers are indolent and remain localized; however, a subset of PCa is aggressive and accounts for more than 27,000 deaths in the United States annually. Identification of factors specifically associated with risk for more aggressive PCa is urgently needed to reduce overdiagnosis and overtreatment of this common disease. To search for such factors, we compared the frequencies of SNPs among PCa patients who were defined as having either more aggressive or less aggressive disease in four populations examined in the Genetic Markers of Susceptibility (CGEMS) study performed by the National Cancer Institute. SNPs showing possible associations with disease severity were further evaluated in an additional three independent study populations from the United States and Sweden. In total, we studied 4,829 and 12,205 patients with more and less aggressive disease, respectively. We found that the frequency of the TT genotype of SNP rs4054823 at 17p12 was consistently higher among patients with more aggressive compared with less aggressive disease in each of the seven populations studied, with an overall P value of 2.1 x 10(-8) under a recessive model, exceeding the conservative genome-wide significance level. The difference in frequency was largest between patients with high-grade, non-organ-confined disease compared with those with low-grade, organ-confined disease. This study demonstrates that inherited variants predisposing to aggressive but not indolent PCa exist in the genome, and suggests that the clinical potential of such variants as potential early markers for risk of aggressive PCa should be evaluated.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 30
Typ av publikation
tidskriftsartikel (25)
konferensbidrag (3)
rapport (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (26)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
Grönberg, Henrik (18)
Wiklund, Fredrik (13)
Xu, Jianfeng (10)
Stattin, Pär (6)
Carlsson, Per (5)
Marklund, Magnus (5)
visa fler...
Gebart, Rikard (5)
Stanford, Janet L (4)
Ostrander, Elaine A. (4)
Boman, Christoffer (4)
Adami, Hans Olov (3)
Schleutker, Johanna (3)
Giles, Graham G (3)
Maier, Christiane (3)
Cannon-Albright, Lis ... (3)
Thibodeau, Stephen N (3)
Severi, Gianluca (3)
Hopper, John L. (3)
Bälter, Katarina (3)
Cooney, Kathleen A. (3)
Eeles, Ros (3)
FitzGerald, Liesel M ... (3)
Emanuelsson, Monica (3)
Schaid, Daniel J (3)
Camp, Nicola J (3)
Foulkes, William D (3)
Whittemore, Alice S (3)
Oakley-Girvan, Ingri ... (3)
Hsieh, Chih-Lin (3)
Sandström, Thomas (2)
Kote-Jarai, Zsofia (2)
Chanock, Stephen J (2)
Mucci, Lorelei A (2)
Cancel-Tassin, Geral ... (2)
Adolfsson, Jan (2)
Holmberg, Erik, 1951 (2)
Kraft, Peter (2)
Swietlicki, Erik (2)
Magnusson, Patrik K ... (2)
Pedersen, Nancy L (2)
Hunter, David J (2)
Hong, Mun-Gwan (2)
Catalona, William J. (2)
Blomberg, Anders (2)
Szulkin, Robert (2)
Tammela, Teuvo (2)
Nyström, Robin (2)
Genberg, Johan (2)
Easton, Douglas (2)
Guy, Michelle (2)
visa färre...
Lärosäte
Karolinska Institutet (18)
Umeå universitet (12)
Göteborgs universitet (7)
Luleå tekniska universitet (7)
Uppsala universitet (5)
RISE (5)
visa fler...
Mälardalens universitet (3)
Lunds universitet (3)
Stockholms universitet (1)
Örebro universitet (1)
Jönköping University (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (28)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (16)
Teknik (8)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy